Literature DB >> 8919275

Analysis of results of surgery performed over a 20-year period on 500 patients with cancer of the thoracic esophagus.

S Abo1, M Kitamura, M Hashimoto, K Izumi, Y Minamiya, T Shikama, H Suzuki, K Temma, S Kamata, R Saito.   

Abstract

This study was conducted to examine the long-term outcome of 500 patients who underwent surgery for cancer of the thoracic esophagus during the past 20 years. Favorable results were obtained with postoperative adjuvant radiation and chemotherapy and there were no surgical deaths in the last 5 years. The mortality rate decreased from 17% prior to 1980 to 5% between 1981 and 1993, this being most probably attributable to the decreased incidence of suture leakage. With respect to changes in surgical techniques, during the initial years we performed intrathoracic anastomosis, after which sternal manubrium resection with anterior mediastinal esophagogastrostomy was carried out. Subsequently, we invented a technique for performing esophagogastrostomy via the posterior mediastinum. The posterior mediastinum was selected as the most physiologic route, based on measurement of tissue oxygen tension. Using blood flow determinations obtained by laser-Doppler velocimetry, we concluded that the effectiveness of thicker gastric tubes was superior to that of thin tubes. Esophagogastrostomy was performed in a shallow field in the cervical region, with the anastomosis ultimately positioned in the superior mediastinum and covered with mediastinal pleura.

Entities:  

Mesh:

Year:  1996        PMID: 8919275     DOI: 10.1007/bf00311768

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  1 in total

1.  Transplantation of the partially resected middle esophagus with a jejunal graft.

Authors:  S KATSURA; Y ISHIKAWA; G OKAYAMA
Journal:  Ann Surg       Date:  1958-02       Impact factor: 12.969

  1 in total
  7 in total

1.  Hand-sewn cervical anastomosis versus stapled intrathoracic anastomosis after esophagectomy for middle or lower thoracic esophageal cancer: a prospective randomized controlled study.

Authors:  Manabu Okuyama; Satoru Motoyama; Hiroyuki Suzuki; Reijiro Saito; Kiyotomi Maruyama; Jun-Ichi Ogawa
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

2.  Long-term survival after salvage resection of recurrent esophageal cancer with anterior mediastinal lymph node involvement: report of a case.

Authors:  Satoru Motoyama; Reijiro Saito; Manabu Okuyama; Kiyotomi Maruyama; Hiroshi Nanjo; Jun-Ichi Ogawa
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck.

Authors:  Satoru Motoyama; Michihiko Kitamura; Reijiro Saito; Kiyotomi Maruyama; Manabu Okuyama; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

4.  Cancer of the gastric tube reconstructed through the posterior mediastinal route after radical surgery for esophageal cancer.

Authors:  H Suzuki; M Kitamura; R Saito; S Motoyama; J Ogawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-07

5.  Mesojejunal lymph node metastasis in esophageal cancer following total gastrectomy.

Authors:  Takashi Ono; Satoru Motoyama; Reijiro Saito; Manabu Okuyama; Hiroshi Imano; Jun-ichi Ogawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-11

6.  Superior mediastinal and neck lymphatic mapping in mid- and lower-thoracic esophageal cancer as defined by ferumoxides-enhanced magnetic resonance imaging.

Authors:  Hiroshi Imano; Satoru Motoyama; Reijiro Saito; Yoshihiro Minamiya; Yoshihisa Katayose; Manabu Okuyama; Masakatsu Nakamura; Koichi Ishiyama; Ryuji Sashi; Jun-ichi Ogawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-10

7.  Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy.

Authors:  Manabu Okuyama; Satoru Motoyama; Kiyotomi Maruyama; Kenji Sasaki; Yusuke Sato; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.